{"ticker": {"uuid": "ad4e9513-b38b-43e9-912d-df665c8fb681", "symbol": "QNCX", "name": "Quince Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug", "summary": "Quince Therapeutics is a clinical-stage biotechnology company developing precision medicines for serious diseases. The company's strategy involves heavy investment in R&D, focusing on targeted mechanisms of action, and navigating a long regulatory path, typical for small-cap biot", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/quince-therapeutics-updates-its-strategy-as-a-clinical-stage-biotech-qncx/69715993", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:40:49", "published_display": "07 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives", "summary": "Quince Therapeutics, Inc. (Nasdaq: QNCX) has engaged LifeSci Capital as its exclusive financial advisor to explore strategic alternatives for maximizing shareholder value, including potential partnerships, mergers, or acquisitions. LifeSci Capital will also advise on any liabilit", "url": "https://www.natlawreview.com/press-releases/quince-therapeutics-engages-lifesci-capital-its-exclusive-financial-advisor", "source_name": "The National Law Review", "published_at": "2026-07-04T19:12:47", "published_display": "04 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics recruits top lung doctors for LAM-001 development", "summary": "Quince Therapeutics (Nasdaq: QNCX) has established a Scientific Advisory Board (SAB) comprising internationally recognized leaders in pulmonary medicine to guide the development of LAM-001. LAM-001 is an inhaled rapamycin targeting serious pulmonary conditions such as PH-ILD, BOS", "url": "https://www.stocktitan.net/news/QNCX/quince-therapeutics-appoints-recognized-leaders-in-pulmonary-fcochw58k6wk.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:10:50", "published_display": "02 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board", "summary": "Quince Therapeutics has appointed Dr. Donald C. Tashkin and Dr. Robert J. Kaner to its newly formed Scientific Advisory Board (SAB) to bolster its idiopathic pulmonary fibrosis (IPF) drug discovery program. These distinguished pulmonologists will provide expert guidance on clinic", "url": "https://www.moomoo.com/news/post/72260387/press-release-quince-therapeutics-appoints-recognized-leaders-in-pulmonary-medicine", "source_name": "Moomoo", "published_at": "2026-07-01T07:09:46", "published_display": "01 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board", "summary": "Quince Therapeutics has established a Scientific Advisory Board (SAB) comprising leading experts in pulmonary medicine to guide the development of LAM-001, an inhaled rapamycin formulation. This SAB will focus on advancing LAM-001 for various pulmonary indications, including PH-I", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319586/0/en/quince-therapeutics-appoints-recognized-leaders-in-pulmonary-medicine-to-scientific-advisory-board.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:40:23", "published_display": "30 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Quince Therapeutics, Inc. \u2013 NASDAQ:QNCX", "summary": "This article provides the \"Price to earnings forward\" metric for Quince Therapeutics, Inc. (NASDAQ: QNCX) sourced from TradingView. It appears to be a financial data snippet rather than a detailed analysis, likely indicating a data point available on the platform for the biotechn", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T21:39:53", "published_display": "29 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Quince Therapeutics, Inc. \u2013 NASDAQ:QNCX", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Quince Therapeutics, Inc. (NASDAQ: QNCX) on TradingView. It indicates that for the measured period, the value is not available, showing \"No trades\" and \"Not available.\" The content is primarily a data plac", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T09:11:12", "published_display": "29 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX)", "summary": "This article provides an overview of Quince Therapeutics, Inc. (NASDAQ: QNCX), covering its stock performance, financial estimates, and key statistics. It details recent price changes, analyst forecasts with high and low estimates, and historical price data. The report also inclu", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-29T07:09:46", "published_display": "29 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Implements 1-for-20 Reverse Stock Split", "summary": "Quince Therapeutics has implemented a 1-for-20 reverse stock split, effective June 29, 2026, consolidating 20 shares into one and reducing the total outstanding shares to approximately 977,963. Trading on a split-adjusted basis began June 30, 2026, with the company retaining its ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/QNCX-Q/pressreleases/3014127/quince-therapeutics-implements-1-for-20-reverse-stock-split/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T17:39:55", "published_display": "27 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction", "summary": "Quince Therapeutics (QNCX) has confirmed a 1-for-20 reverse stock split, reducing its outstanding common shares from 19,559,257 to approximately 977,963. The split, effective June 29, 2026, with split-adjusted trading starting June 30, 2026, will not alter percentage ownership or", "url": "https://www.stocktitan.net/sec-filings/QNCX/8-k-a-quince-therapeutics-inc-amends-material-event-report-29d1c410c60f.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:39", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares", "summary": "Quince Therapeutics (NASDAQ: QNCX) has implemented a 1-for-20 reverse stock split, effective 11:59 p.m. Eastern Time on June 29, 2026, with trading on a split-adjusted basis beginning June 30, 2026. This action reduces the number of outstanding shares from approximately 19.56 mil", "url": "https://www.stocktitan.net/sec-filings/QNCX/8-k-quince-therapeutics-inc-reports-material-event-e6dd88108e47.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:40:01", "published_display": "26 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Quince Therapeutics, Inc. \u2013 NASDAQ:QNCX", "summary": "This page displays the \"Price to sales forward\" financial metric for Quince Therapeutics, Inc. (NASDAQ: QNCX). It indicates the value and change over a specific period for this financial ratio. The content is presented by TradingView, a financial platform offering market data and", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:40:01", "published_display": "26 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Quince Therapeutics (NASDAQ:QNCX) with a $4.00 price target, following the company's recent reverse merger acquisition of Orphai Therapeutics. Despite high stock volatility and a 97% year-to-date decline, the firm views Qui", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-quince-therapeutics-stock-overweight-rating-93CH-4760553", "source_name": "Investing.com", "published_at": "2026-06-25T14:40:01", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight", "summary": "Cantor Fitzgerald has reiterated an Overweight rating for Quince Therapeutics Inc. (NASDAQ:QNCX), setting a price target of $4.00 for the combined entity after its reverse merger with Orphai Therapeutics. Despite the company's current low market capitalization and significant sto", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-quince-therapeutics-stock-rating-at-overweight-93CH-4760547", "source_name": "Investing.com", "published_at": "2026-06-25T13:13:49", "published_display": "25 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Quince Therapeutics (NASDAQ:QNCX) with a $4.00 price target. This follows Quince's acquisition of Orphai Therapeutics through a reverse merger and positive results from a phase 2a study of LAM-001 for pulmonary hypertension", "url": "https://au.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-quince-therapeutics-stock-overweight-rating-93CH-4504710", "source_name": "Investing.com Australia", "published_at": "2026-06-25T12:13:49", "published_display": "25 Jun 2026 12:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Quince Therapeutics (QNCX.US)$", "summary": "The article is a brief post from the moomoo Community discussing Quince Therapeutics (QNCX.US). It appears to be a user-generated content focused on the stock. The author, \u6625\u590f\u79cb\u51ac\u51ac, commented on the stock on June 25th.", "url": "https://www.moomoo.com/community/feed/quince-therapeutics-qncx-us-116808071315862", "source_name": "Moomoo", "published_at": "2026-06-25T03:40:26", "published_display": "25 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4", "summary": "Leerink Partners has initiated coverage on Quince Therapeutics (QNCX.US) with a Buy rating. The financial firm also set a price target of $4 for the company's stock.", "url": "https://www.moomoo.com/news/post/71964419/leerink-partners-initiates-quince-therapeutics-qncxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-24T19:09:42", "published_display": "24 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target", "summary": "Leerink Partners has initiated coverage on Quince Therapeutics with an Outperform rating and a $4 price target. The biotechnology company, specializing in treatments for rare diseases, is currently trading at approximately $0.97 per share. Analysts' consensus rates QNCX as \"Outpe", "url": "https://www.marketscreener.com/news/leerink-partners-initiates-quince-therapeutics-at-outperform-with-4-price-target-ce7f5fdbdf8dfe23", "source_name": "marketscreener.com", "published_at": "2026-06-24T11:42:12", "published_display": "24 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Quince Therapeutics stock with Outperform rating", "summary": "Leerink has initiated coverage on Quince Therapeutics Inc. (NASDAQ:QNCX) with an Outperform rating and a $4.00 price target, suggesting substantial upside from its current $0.97 stock price. The valuation comes after Quince's acquisition of Orphai Therapeutics, making it a clinic", "url": "https://www.investing.com/news/analyst-ratings/leerink-initiates-quince-therapeutics-stock-with-outperform-rating-93CH-4757835", "source_name": "Investing.com", "published_at": "2026-06-24T11:42:12", "published_display": "24 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Overweight", "summary": "Cantor Fitzgerald initiated coverage on Quince Therapeutics (QNCX) with an \"Overweight\" rating and a $4.00 price target. Despite a low GF Score\u2122 of 21/100, indicating potential long-term return challenges, the company's financial strength is rated 7/10. The positive analyst outlo", "url": "https://www.gurufocus.com/news/8928118/qncx-initiated-coverage-by-cantor-fitzgerald-rating-set-to-overweight?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-23T18:40:24", "published_display": "23 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for Quince Therapeutics Inc. (QNCX) on NASDAQ, showing its current price as $0.9879 with a 2.03% increase. It includes a basic price history chart and notes that there are no analyst ratings or earnings information currently availab", "url": "https://stockstotrade.com/quote/QNCX", "source_name": "StocksToTrade", "published_at": "2026-06-23T16:42:12", "published_display": "23 Jun 2026 16:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating", "summary": "Cantor Fitzgerald initiated coverage on Quince Therapeutics Inc. (NASDAQ:QNCX) with an overweight rating and a $4.00 price target. The firm noted Quince's recent reverse merger with Orphai Therapeutics and its focus on pulmonary hypertension treatments, characterizing it as a com", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-initiates-quince-therapeutics-stock-with-overweight-rating-93CH-4755330", "source_name": "Investing.com", "published_at": "2026-06-23T13:42:13", "published_display": "23 Jun 2026 13:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4", "summary": "Cantor Fitzgerald has initiated coverage on Quince Therapeutics (QNCX.US) with a Buy rating. The firm has set a target price of $4 for the company's stock. This initiation suggests a positive outlook on Quince Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/71892091/cantor-fitzgerald-initiates-quince-therapeutics-qncxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-23T10:39:31", "published_display": "23 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Quince Therapeutics Inc (QNCX). It notes that the company has distributed $0.00 in dividends over the past five years and details a 10-to-1 merger stock split scheduled for April 9, 2026. The page also disp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:41", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Quince Therapeutics Inc (QNCX) shareholder structure, detailing major individual and institutional holdings. It lists the top shareholders and categorizes shareholder types by proportion, also presenting historical institutional shareholding d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:19:20", "published_display": "18 Jun 2026 09:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Quince Therapeutics Inc (QNCX), including analyst ratings, price targets, and historical/projected EPS and revenue data. Three analysts currently rate the stock as \"Hold\" with a target price of $8.00, suggesting an upside of over 870", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T00:09:16", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on the revenue breakdown for Quince Therapeutics Inc (QNCX). It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides genera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:19:21", "published_display": "17 Jun 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a current valuation analysis for Quince Therapeutics Inc (QNCX), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. As of the report, relevant data for these valuation metrics have not been disclosed by the company, indicating limited current finan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T12:09:52", "published_display": "17 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Quince Therapeutics Inc (QNCX), including current share price, market capitalization, and P/E ratio. It lists the top institutional shareholders, their shareholdings, and the percentage change in their positions. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T08:09:26", "published_display": "17 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) director receives 2,700 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPOUhnSnM4eC1IUGxYMDBGam9vN3doelQ5TG9UdFhreXJTMXpMY2JjLThpcjZESFZQZWNtelRqVE1jUnhCUUVuUjJHV1pCRU9zMDdQc2pRdnU2Y3JURk9zaXJMLU83RFZUYWhmU2pmYlUwWjIyZmtuczQ5TWJHYUdEWE1jZDVjX29EaTBLSjhmd0JoOTdDS1RiS2N5TWVwNUxfT3ZOa1U1UzV0WTBVak1lOG1SZ3cxSFQy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) director granted stock options for 2,700 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdkdGS0JIaXMzT19EaU1ZLXY5Q3dsRUFKd3Bjcy1jY2ZRQm4tdF9ndkU2aVhIUGZxeGptTmFDR2JITFBsaFdSNEx2RTQzOVNDdXNxelcxQzNTQ1dfVnBkVk1ZYndCaXpEZzdCN1lWeVlka1Jnc2stcGlaelN3bVA5Wk0tSkRJeXhlX0FLU25hdTZlcktkYnJHelNfSlF6amR6djdyeUVuSXRkamYtU0FaNno5bmVuWVEy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNVGM2eklsRDktd0FVRlZCWWtEdWVxckx1b0NYZ3VvN2g5aENEN1dyMmlpQnFtZl9fU3NyQnJSTi1yQ01EMEpwbHBaTGZGa19hdjA5eHdxTmNYSXBwTzgxLXBIWUpzRGhzN3Z6aHgzY18tTEM3ZE1tVlJjSUNnbWI4QzJJWnVmRXhsMEtFMFRRX2JCN3Z2UFkyaklxUzh5REMxY1l6ZHVuMFBucm5HWkJzeXZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOUtOSnVlWmpxTWFENldWRWF4R0FmS2ozNUx1QjgtdUZ4Nnh3dnhIRDFYZWVhalEtM0RES3dhbzFVd1VPMEZ5aENyTGgyRlloUUdBam84cWthZDBkcmZZUWZOemNMUElHMUNoLWxHU1hLYkVLbWZnM0VtUHFHeHdPblE1RmtUVmNiVFRNSGtYRWhjYjNhWmJWU19oV3Y4bEt0YmpDUTluZnJ0dw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quince-therapeutics-announces-clinically-meaningful-142100139.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T14:21:00+00:00", "published_display": "18 May 2026 14:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quince-therapeutics-announces-clinically-meaningful-132600133.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T13:26:00+00:00", "published_display": "18 May 2026 13:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quince-announces-acquisition-orphai-187-132600523.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T13:26:00+00:00", "published_display": "18 May 2026 13:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Quince Therapeutics Announces 1-for-10 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPN3R5dVFqNU1EbVdCbUhGamY1YXBCb0N5WXdXdmVvWklmRl9kV29ELVVMUlg4S0kwOGlUMW9HSDVjd2VOTEF6TWdTYVBfampxZi1qRndqZks0eXZ1MThOREZ4UTNJa1M1OGk5RmtVa196YjNFRlVGbWw5QWo1dlc4c09zMEhJRVhtMU10TUo3c2lDR0RuRGdrSnd6OHZTN043X0s2VnpuZkRtMVJkRHVoUjBUTUdJS1BHSU1EWmNDWUR3b3Y2NGh2ZmtBQk92aGw0d2hsaUJXRDIwQkE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $5.5M payment erased Quince debt as it explores merger options", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQOTg0VjZLYnBLOHlkODRBcUh2U0s4aFNPcHBRSWc0Y1BHT0d2X1JyNDdFSlQ2UTROUU9VclhFdUZsbmVmTjVnTmdkdUdva2FENE5zWEd3MmxSYlB3SVFmYU5WTVYtY0lleDdlMExsdURpb3NZYm82Z2lteGxpaWxaVXNxTzBCOThia05mRTk0SlFVSEt4aWxCVVE5MG9HUklsRlJmNnNhblNfbG1xN1Rlb25R?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOGo2Y21PRjBFcHY0QVdSZ1BQOVFyVVYwZmpublZFLXY5cU5nMmhXVVNSbmJQWlZETHhydDFQM1pJR0hNXzVIQWZYN0d0ZlB1NTh2cGJVZk1LVnhsa0EtMTk1cXp6bUlqRU04Unk5TjJubkNndk00ckRhYXJqSERldGpPbUhIby1UcnhWNWFHOXJxakJSOXpyTWlLMVlhWlZUcXliMjhYZFQxWi1qOVNud0pBSFVDMnlKb1E?oc=5", "source_name": "Sahm", "published_at": "2026-02-18T15:18:22+00:00", "published_display": "18 Feb 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lead drug failure leaves Quince (QNCX) banking on reverse merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOWVZJdUYwbThCeExObWtKUVFvSTVqazBadnBadGxpWGQ1Zzdjb1dTVzhHT2xXekgweFFPTzZYaExMX1YwZVltcjNZZFJKSTRkXzQzc2llOFdVVnppR0g3eVo2djZzcWZWLTZUVmxWNGFZNy16R1NnWVhWREg1RC1IaHR5Qkh3aEFudVhSTDg2aFJyQWRiQTVuSWM0cnR0cmVSdmZodmI4WWs1OF9wdmtNYkVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics stock plummets after revealing strategic alternatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdlBjNHJUeGhuRGVWRmZ5RUhTMHljZVdBOGRldjhzd1NWZkNjbVhfMWxNNF80TnpLTHNuNkdLN3ZVTFdnSUxPMFBHMlZhSzhOTXhiTDdBN2NQU04xb2QwRHpvbkxwRzVqSFFndUJXdnZyN2JaYzF6LXl3VDhQdzBmYVAwSmxwUFJXNk9oZ1ZZLXU4Tm5yMkY0ZmxwSHBiWjhta0l2QXpWVXhDLTdrVXRSQ0g2VTEyczZSc2ZWRklPU25sUlBSSWtsWnFuTHRHZUQ5?oc=5", "source_name": "Investing.com", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQN0o0WnJULWF1RFpIVGpMR2ppYlhtZU9Lb0ZrWWRDR25UZGl5aEg3a2JoQVBNd3d0M3VOeFBzQ1Z5c3NsVFZwZ3RRWHhPNWNRTDQ4SWFUckpwZHpUb2dEakJLeW5vczBqU3hRQ1hzZXFNemQ4bDlKVnM3OXEwcEJXMTVTdHRZWEYtOVNfcmFxa0tDbUtWWE5kOXZaWGJsMWFnM1FuN2xqZFRTMWVWVzJnVUpuNUcxalQ2cjVCYlpmUDJrNXplU1I3anpTc0htQWRjakpKcXdn?oc=5", "source_name": "Sahm", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince stock plunges 95% following failed clinical trial for inherited childhood disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPZmY4Mzl1RHpfRDYzNTEwSXBZOExKcmV4ZjBQSjFuM25kNUswaXZXYkRWaTZDaE52LWhJTThTSDgyRWkzTEQtRktTUFd1QXFfRFd4R1NpV0VfcW1YR19admVjVU5ZbEJTT2FJU083ZlNOeFJuSU9NelJZenVZMHhFbnY5bFVzWTI1VVR3RXdTRnZoNm4zdmtab19LX1ZWODhIXzllalVlbjBRLVJaSGN6N2tn?oc=5", "source_name": "The Business Journals", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics stock tumbles after failed Phase 3 trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQVjVTYVVFV0RndHcxTHUtRzhDOGVQUEN1b0JxcDhoREItWkdIdlhYNDhlSk5oYTR1SzdRblU5OE40MG0xcm52d295cnNRbUJVY2hfanVFT0Rtc2FUanBkTmQzOTdQYllRdDlxTG9FS0lqUkg0MkJBUlVHa3hFT1dSRDBDZlA5amd5dlA4TEtVcVFWUkx3X19aRFl2R0JaN2ExQ2F4NldHN3U3UkUxSFAxeTFkSlhyRkxGazgyNm9YeGFQdjVneVduMXZB?oc=5", "source_name": "Investing.com", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare disease hope stalls as eDSP trial fails and Quince halts development", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMjF5VTJaWWxBREY2Y3dFMnF4bnFrY29wRi1QbFJXd3JCVkF3TTlwQXpZbHUtQVRkUmFVUm9WWWMxcDVUN215TTFPZzcyeUNuT1JhUU5ZVmtuR3ZhTmdJcmVHbnJaamlsTXByZUw4Nk1MU3RXT1B0RG1uclBXalhtLVZ2NWFiN05aSjhaMkRUNzFzYzZlbmhEdkt3MW1ZNk5DaVozZjdtUnRtRlVLWGZvR0RlSHpIeDAtcGxZYUVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxONEtFd1ZQbC1MNUxYa0FWMF9MY3EyQ2w4MkVENnUwTVBEVjJVb1h4bU1nQkU0c05ZRW1wSHJMZHFVM0tOci0tRzA0cjBnZVgzaXg5NUJ1WDc3NGxjR3RZUFlWRkU3MGRlcDN4T0g0NG5yUnJYTkpnekRmQ0Q1dGR0cXNDRE9OcmF6VmwwVS1aLUE3ZnJRNU1HUnZCMXU0UFA3LXRvQ29XZTdBMlY2MlFqSklkVm5ib185em9TWm9ZMUlLNGpJcXMyVzhzOW9GajE0V3lmcy1XS0YzV2xnb2E40gHkAUFVX3lxTE9aQXd6NHQtOUJPcUFEYzN2dG9XQ0FfWExOVUNCZ0RjUDdmMVdNLU1KeFVyUzVES3p0MnlxZlJGZXdnNnFDUm9LbHAxNURiamdBMEVDTnNmX1c1MGQ5TkQxLV9HYnlGOGRuRW43NVdBVWduXzJLXzNnYlFPaWxEbVhGR0lHd3hFVGhtdERhWmtuc2dMRS1EckJPb19DWktlOXk1U3IybElBZTRDMGQ4ZnJTNDhzSG5GWFowUFJ1OURqeUdIaUMyckVqaDV3RkNGNFY4dnp3RWxENUUxY3ZfenBSYWdKdw?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPSmpab2VPd0N3TGMtX3p3QTJjQmFQekFHWkFUd29VckdQMWRqc1F3SWxweFR2ang4Rl9SLXpfb1lQeVEzSVJGbVg2ZVVPTkQ2Z2hMSjI3dlZ5ekVTVnB0WFc1RkttLURBZkVaczNIcWZUcXo3OHZuakp3cU1xazhFeWliVGFETEU5YWw4bEJoUXlkeHM4YTIwREI2Z25NQ3NKRTFvakgxcnhuZXpfWjQ4VDRXamJ6MmswTGZuLXhFelllNDFrWkxhZnM4SzJ6Rl9xVUx0X1R6Zl9vcGhoTzhKNzg0aw?oc=5", "source_name": "Business Wire", "published_at": "2025-06-12T07:00:00+00:00", "published_display": "12 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince (QNCX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE0xZ3pSN29sR0NyamFHRHpBbElsN0ZRUm15d3h2TDh0VU4waUxRcUpEeS1ha0Zmcm01Tnc0R2pEd2RhTVh1dWNEaVVFVkcwVk5QYjl3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:36:57+00:00", "published_display": "25 Apr 2025 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBBNTY1cjVJSEliZkFkQnNkWE5SNDRGZ0VYcmRXMEhKaWhEd05uZnpfdllNN29iMFFNSlJUZmt0V3pweUdBVXhCaE9ZOW44OWxfeGhOU0dlbzlDZw?oc=5", "source_name": "MarketBeat", "published_at": "2022-08-04T13:01:09+00:00", "published_display": "04 Aug 2022 13:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug", "summary": "Quince Therapeutics is a clinical-stage biotechnology company developing precision medicines for serious diseases. The company's strategy involves heavy investment in R&D, focusing on targeted mechanisms of action, and navigating a long regulatory path, typical for small-cap biot", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/quince-therapeutics-updates-its-strategy-as-a-clinical-stage-biotech-qncx/69715993", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:40:49", "published_display": "07 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives", "summary": "Quince Therapeutics, Inc. (Nasdaq: QNCX) has engaged LifeSci Capital as its exclusive financial advisor to explore strategic alternatives for maximizing shareholder value, including potential partnerships, mergers, or acquisitions. LifeSci Capital will also advise on any liabilit", "url": "https://www.natlawreview.com/press-releases/quince-therapeutics-engages-lifesci-capital-its-exclusive-financial-advisor", "source_name": "The National Law Review", "published_at": "2026-07-04T19:12:47", "published_display": "04 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics recruits top lung doctors for LAM-001 development", "summary": "Quince Therapeutics (Nasdaq: QNCX) has established a Scientific Advisory Board (SAB) comprising internationally recognized leaders in pulmonary medicine to guide the development of LAM-001. LAM-001 is an inhaled rapamycin targeting serious pulmonary conditions such as PH-ILD, BOS", "url": "https://www.stocktitan.net/news/QNCX/quince-therapeutics-appoints-recognized-leaders-in-pulmonary-fcochw58k6wk.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:10:50", "published_display": "02 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board", "summary": "Quince Therapeutics has appointed Dr. Donald C. Tashkin and Dr. Robert J. Kaner to its newly formed Scientific Advisory Board (SAB) to bolster its idiopathic pulmonary fibrosis (IPF) drug discovery program. These distinguished pulmonologists will provide expert guidance on clinic", "url": "https://www.moomoo.com/news/post/72260387/press-release-quince-therapeutics-appoints-recognized-leaders-in-pulmonary-medicine", "source_name": "Moomoo", "published_at": "2026-07-01T07:09:46", "published_display": "01 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board", "summary": "Quince Therapeutics has established a Scientific Advisory Board (SAB) comprising leading experts in pulmonary medicine to guide the development of LAM-001, an inhaled rapamycin formulation. This SAB will focus on advancing LAM-001 for various pulmonary indications, including PH-I", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319586/0/en/quince-therapeutics-appoints-recognized-leaders-in-pulmonary-medicine-to-scientific-advisory-board.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:40:23", "published_display": "30 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Quince Therapeutics, Inc. \u2013 NASDAQ:QNCX", "summary": "This article provides the \"Price to earnings forward\" metric for Quince Therapeutics, Inc. (NASDAQ: QNCX) sourced from TradingView. It appears to be a financial data snippet rather than a detailed analysis, likely indicating a data point available on the platform for the biotechn", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T21:39:53", "published_display": "29 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Quince Therapeutics, Inc. \u2013 NASDAQ:QNCX", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Quince Therapeutics, Inc. (NASDAQ: QNCX) on TradingView. It indicates that for the measured period, the value is not available, showing \"No trades\" and \"Not available.\" The content is primarily a data plac", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T09:11:12", "published_display": "29 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX)", "summary": "This article provides an overview of Quince Therapeutics, Inc. (NASDAQ: QNCX), covering its stock performance, financial estimates, and key statistics. It details recent price changes, analyst forecasts with high and low estimates, and historical price data. The report also inclu", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-29T07:09:46", "published_display": "29 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Implements 1-for-20 Reverse Stock Split", "summary": "Quince Therapeutics has implemented a 1-for-20 reverse stock split, effective June 29, 2026, consolidating 20 shares into one and reducing the total outstanding shares to approximately 977,963. Trading on a split-adjusted basis began June 30, 2026, with the company retaining its ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/QNCX-Q/pressreleases/3014127/quince-therapeutics-implements-1-for-20-reverse-stock-split/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T17:39:55", "published_display": "27 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction", "summary": "Quince Therapeutics (QNCX) has confirmed a 1-for-20 reverse stock split, reducing its outstanding common shares from 19,559,257 to approximately 977,963. The split, effective June 29, 2026, with split-adjusted trading starting June 30, 2026, will not alter percentage ownership or", "url": "https://www.stocktitan.net/sec-filings/QNCX/8-k-a-quince-therapeutics-inc-amends-material-event-report-29d1c410c60f.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:39", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares", "summary": "Quince Therapeutics (NASDAQ: QNCX) has implemented a 1-for-20 reverse stock split, effective 11:59 p.m. Eastern Time on June 29, 2026, with trading on a split-adjusted basis beginning June 30, 2026. This action reduces the number of outstanding shares from approximately 19.56 mil", "url": "https://www.stocktitan.net/sec-filings/QNCX/8-k-quince-therapeutics-inc-reports-material-event-e6dd88108e47.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:40:01", "published_display": "26 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Quince Therapeutics, Inc. \u2013 NASDAQ:QNCX", "summary": "This page displays the \"Price to sales forward\" financial metric for Quince Therapeutics, Inc. (NASDAQ: QNCX). It indicates the value and change over a specific period for this financial ratio. The content is presented by TradingView, a financial platform offering market data and", "url": "https://www.tradingview.com/symbols/NASDAQ-QNCX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:40:01", "published_display": "26 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Quince Therapeutics (NASDAQ:QNCX) with a $4.00 price target, following the company's recent reverse merger acquisition of Orphai Therapeutics. Despite high stock volatility and a 97% year-to-date decline, the firm views Qui", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-quince-therapeutics-stock-overweight-rating-93CH-4760553", "source_name": "Investing.com", "published_at": "2026-06-25T14:40:01", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight", "summary": "Cantor Fitzgerald has reiterated an Overweight rating for Quince Therapeutics Inc. (NASDAQ:QNCX), setting a price target of $4.00 for the combined entity after its reverse merger with Orphai Therapeutics. Despite the company's current low market capitalization and significant sto", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-quince-therapeutics-stock-rating-at-overweight-93CH-4760547", "source_name": "Investing.com", "published_at": "2026-06-25T13:13:49", "published_display": "25 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Quince Therapeutics (NASDAQ:QNCX) with a $4.00 price target. This follows Quince's acquisition of Orphai Therapeutics through a reverse merger and positive results from a phase 2a study of LAM-001 for pulmonary hypertension", "url": "https://au.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-quince-therapeutics-stock-overweight-rating-93CH-4504710", "source_name": "Investing.com Australia", "published_at": "2026-06-25T12:13:49", "published_display": "25 Jun 2026 12:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Quince Therapeutics (QNCX.US)$", "summary": "The article is a brief post from the moomoo Community discussing Quince Therapeutics (QNCX.US). It appears to be a user-generated content focused on the stock. The author, \u6625\u590f\u79cb\u51ac\u51ac, commented on the stock on June 25th.", "url": "https://www.moomoo.com/community/feed/quince-therapeutics-qncx-us-116808071315862", "source_name": "Moomoo", "published_at": "2026-06-25T03:40:26", "published_display": "25 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4", "summary": "Leerink Partners has initiated coverage on Quince Therapeutics (QNCX.US) with a Buy rating. The financial firm also set a price target of $4 for the company's stock.", "url": "https://www.moomoo.com/news/post/71964419/leerink-partners-initiates-quince-therapeutics-qncxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-24T19:09:42", "published_display": "24 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target", "summary": "Leerink Partners has initiated coverage on Quince Therapeutics with an Outperform rating and a $4 price target. The biotechnology company, specializing in treatments for rare diseases, is currently trading at approximately $0.97 per share. Analysts' consensus rates QNCX as \"Outpe", "url": "https://www.marketscreener.com/news/leerink-partners-initiates-quince-therapeutics-at-outperform-with-4-price-target-ce7f5fdbdf8dfe23", "source_name": "marketscreener.com", "published_at": "2026-06-24T11:42:12", "published_display": "24 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Quince Therapeutics stock with Outperform rating", "summary": "Leerink has initiated coverage on Quince Therapeutics Inc. (NASDAQ:QNCX) with an Outperform rating and a $4.00 price target, suggesting substantial upside from its current $0.97 stock price. The valuation comes after Quince's acquisition of Orphai Therapeutics, making it a clinic", "url": "https://www.investing.com/news/analyst-ratings/leerink-initiates-quince-therapeutics-stock-with-outperform-rating-93CH-4757835", "source_name": "Investing.com", "published_at": "2026-06-24T11:42:12", "published_display": "24 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Overweight", "summary": "Cantor Fitzgerald initiated coverage on Quince Therapeutics (QNCX) with an \"Overweight\" rating and a $4.00 price target. Despite a low GF Score\u2122 of 21/100, indicating potential long-term return challenges, the company's financial strength is rated 7/10. The positive analyst outlo", "url": "https://www.gurufocus.com/news/8928118/qncx-initiated-coverage-by-cantor-fitzgerald-rating-set-to-overweight?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-23T18:40:24", "published_display": "23 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for Quince Therapeutics Inc. (QNCX) on NASDAQ, showing its current price as $0.9879 with a 2.03% increase. It includes a basic price history chart and notes that there are no analyst ratings or earnings information currently availab", "url": "https://stockstotrade.com/quote/QNCX", "source_name": "StocksToTrade", "published_at": "2026-06-23T16:42:12", "published_display": "23 Jun 2026 16:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating", "summary": "Cantor Fitzgerald initiated coverage on Quince Therapeutics Inc. (NASDAQ:QNCX) with an overweight rating and a $4.00 price target. The firm noted Quince's recent reverse merger with Orphai Therapeutics and its focus on pulmonary hypertension treatments, characterizing it as a com", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-initiates-quince-therapeutics-stock-with-overweight-rating-93CH-4755330", "source_name": "Investing.com", "published_at": "2026-06-23T13:42:13", "published_display": "23 Jun 2026 13:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4", "summary": "Cantor Fitzgerald has initiated coverage on Quince Therapeutics (QNCX.US) with a Buy rating. The firm has set a target price of $4 for the company's stock. This initiation suggests a positive outlook on Quince Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/71892091/cantor-fitzgerald-initiates-quince-therapeutics-qncxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-23T10:39:31", "published_display": "23 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Quince Therapeutics Inc (QNCX). It notes that the company has distributed $0.00 in dividends over the past five years and details a 10-to-1 merger stock split scheduled for April 9, 2026. The page also disp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:41", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Quince Therapeutics Inc (QNCX) shareholder structure, detailing major individual and institutional holdings. It lists the top shareholders and categorizes shareholder types by proportion, also presenting historical institutional shareholding d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:19:20", "published_display": "18 Jun 2026 09:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Quince Therapeutics Inc (QNCX), including analyst ratings, price targets, and historical/projected EPS and revenue data. Three analysts currently rate the stock as \"Hold\" with a target price of $8.00, suggesting an upside of over 870", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T00:09:16", "published_display": "18 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on the revenue breakdown for Quince Therapeutics Inc (QNCX). It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides genera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:19:21", "published_display": "17 Jun 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a current valuation analysis for Quince Therapeutics Inc (QNCX), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. As of the report, relevant data for these valuation metrics have not been disclosed by the company, indicating limited current finan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T12:09:52", "published_display": "17 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc (QNCX) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Quince Therapeutics Inc (QNCX), including current share price, market capitalization, and P/E ratio. It lists the top institutional shareholders, their shareholdings, and the percentage change in their positions. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qncx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T08:09:26", "published_display": "17 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) director receives 2,700 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPOUhnSnM4eC1IUGxYMDBGam9vN3doelQ5TG9UdFhreXJTMXpMY2JjLThpcjZESFZQZWNtelRqVE1jUnhCUUVuUjJHV1pCRU9zMDdQc2pRdnU2Y3JURk9zaXJMLU83RFZUYWhmU2pmYlUwWjIyZmtuczQ5TWJHYUdEWE1jZDVjX29EaTBLSjhmd0JoOTdDS1RiS2N5TWVwNUxfT3ZOa1U1UzV0WTBVak1lOG1SZ3cxSFQy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) director granted stock options for 2,700 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdkdGS0JIaXMzT19EaU1ZLXY5Q3dsRUFKd3Bjcy1jY2ZRQm4tdF9ndkU2aVhIUGZxeGptTmFDR2JITFBsaFdSNEx2RTQzOVNDdXNxelcxQzNTQ1dfVnBkVk1ZYndCaXpEZzdCN1lWeVlka1Jnc2stcGlaelN3bVA5Wk0tSkRJeXhlX0FLU25hdTZlcktkYnJHelNfSlF6amR6djdyeUVuSXRkamYtU0FaNno5bmVuWVEy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNVGM2eklsRDktd0FVRlZCWWtEdWVxckx1b0NYZ3VvN2g5aENEN1dyMmlpQnFtZl9fU3NyQnJSTi1yQ01EMEpwbHBaTGZGa19hdjA5eHdxTmNYSXBwTzgxLXBIWUpzRGhzN3Z6aHgzY18tTEM3ZE1tVlJjSUNnbWI4QzJJWnVmRXhsMEtFMFRRX2JCN3Z2UFkyaklxUzh5REMxY1l6ZHVuMFBucm5HWkJzeXZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOUtOSnVlWmpxTWFENldWRWF4R0FmS2ozNUx1QjgtdUZ4Nnh3dnhIRDFYZWVhalEtM0RES3dhbzFVd1VPMEZ5aENyTGgyRlloUUdBam84cWthZDBkcmZZUWZOemNMUElHMUNoLWxHU1hLYkVLbWZnM0VtUHFHeHdPblE1RmtUVmNiVFRNSGtYRWhjYjNhWmJWU19oV3Y4bEt0YmpDUTluZnJ0dw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quince-therapeutics-announces-clinically-meaningful-142100139.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T14:21:00+00:00", "published_display": "18 May 2026 14:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quince-therapeutics-announces-clinically-meaningful-132600133.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T13:26:00+00:00", "published_display": "18 May 2026 13:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quince-announces-acquisition-orphai-187-132600523.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T13:26:00+00:00", "published_display": "18 May 2026 13:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Announces 1-for-10 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPN3R5dVFqNU1EbVdCbUhGamY1YXBCb0N5WXdXdmVvWklmRl9kV29ELVVMUlg4S0kwOGlUMW9HSDVjd2VOTEF6TWdTYVBfampxZi1qRndqZks0eXZ1MThOREZ4UTNJa1M1OGk5RmtVa196YjNFRlVGbWw5QWo1dlc4c09zMEhJRVhtMU10TUo3c2lDR0RuRGdrSnd6OHZTN043X0s2VnpuZkRtMVJkRHVoUjBUTUdJS1BHSU1EWmNDWUR3b3Y2NGh2ZmtBQk92aGw0d2hsaUJXRDIwQkE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $5.5M payment erased Quince debt as it explores merger options", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQOTg0VjZLYnBLOHlkODRBcUh2U0s4aFNPcHBRSWc0Y1BHT0d2X1JyNDdFSlQ2UTROUU9VclhFdUZsbmVmTjVnTmdkdUdva2FENE5zWEd3MmxSYlB3SVFmYU5WTVYtY0lleDdlMExsdURpb3NZYm82Z2lteGxpaWxaVXNxTzBCOThia05mRTk0SlFVSEt4aWxCVVE5MG9HUklsRlJmNnNhblNfbG1xN1Rlb25R?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPOGo2Y21PRjBFcHY0QVdSZ1BQOVFyVVYwZmpublZFLXY5cU5nMmhXVVNSbmJQWlZETHhydDFQM1pJR0hNXzVIQWZYN0d0ZlB1NTh2cGJVZk1LVnhsa0EtMTk1cXp6bUlqRU04Unk5TjJubkNndk00ckRhYXJqSERldGpPbUhIby1UcnhWNWFHOXJxakJSOXpyTWlLMVlhWlZUcXliMjhYZFQxWi1qOVNud0pBSFVDMnlKb1E?oc=5", "source_name": "Sahm", "published_at": "2026-02-18T15:18:22+00:00", "published_display": "18 Feb 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lead drug failure leaves Quince (QNCX) banking on reverse merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOWVZJdUYwbThCeExObWtKUVFvSTVqazBadnBadGxpWGQ1Zzdjb1dTVzhHT2xXekgweFFPTzZYaExMX1YwZVltcjNZZFJKSTRkXzQzc2llOFdVVnppR0g3eVo2djZzcWZWLTZUVmxWNGFZNy16R1NnWVhWREg1RC1IaHR5Qkh3aEFudVhSTDg2aFJyQWRiQTVuSWM0cnR0cmVSdmZodmI4WWs1OF9wdmtNYkVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics stock plummets after revealing strategic alternatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdlBjNHJUeGhuRGVWRmZ5RUhTMHljZVdBOGRldjhzd1NWZkNjbVhfMWxNNF80TnpLTHNuNkdLN3ZVTFdnSUxPMFBHMlZhSzhOTXhiTDdBN2NQU04xb2QwRHpvbkxwRzVqSFFndUJXdnZyN2JaYzF6LXl3VDhQdzBmYVAwSmxwUFJXNk9oZ1ZZLXU4Tm5yMkY0ZmxwSHBiWjhta0l2QXpWVXhDLTdrVXRSQ0g2VTEyczZSc2ZWRklPU25sUlBSSWtsWnFuTHRHZUQ5?oc=5", "source_name": "Investing.com", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQN0o0WnJULWF1RFpIVGpMR2ppYlhtZU9Lb0ZrWWRDR25UZGl5aEg3a2JoQVBNd3d0M3VOeFBzQ1Z5c3NsVFZwZ3RRWHhPNWNRTDQ4SWFUckpwZHpUb2dEakJLeW5vczBqU3hRQ1hzZXFNemQ4bDlKVnM3OXEwcEJXMTVTdHRZWEYtOVNfcmFxa0tDbUtWWE5kOXZaWGJsMWFnM1FuN2xqZFRTMWVWVzJnVUpuNUcxalQ2cjVCYlpmUDJrNXplU1I3anpTc0htQWRjakpKcXdn?oc=5", "source_name": "Sahm", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince stock plunges 95% following failed clinical trial for inherited childhood disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPZmY4Mzl1RHpfRDYzNTEwSXBZOExKcmV4ZjBQSjFuM25kNUswaXZXYkRWaTZDaE52LWhJTThTSDgyRWkzTEQtRktTUFd1QXFfRFd4R1NpV0VfcW1YR19admVjVU5ZbEJTT2FJU083ZlNOeFJuSU9NelJZenVZMHhFbnY5bFVzWTI1VVR3RXdTRnZoNm4zdmtab19LX1ZWODhIXzllalVlbjBRLVJaSGN6N2tn?oc=5", "source_name": "The Business Journals", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics stock tumbles after failed Phase 3 trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQVjVTYVVFV0RndHcxTHUtRzhDOGVQUEN1b0JxcDhoREItWkdIdlhYNDhlSk5oYTR1SzdRblU5OE40MG0xcm52d295cnNRbUJVY2hfanVFT0Rtc2FUanBkTmQzOTdQYllRdDlxTG9FS0lqUkg0MkJBUlVHa3hFT1dSRDBDZlA5amd5dlA4TEtVcVFWUkx3X19aRFl2R0JaN2ExQ2F4NldHN3U3UkUxSFAxeTFkSlhyRkxGazgyNm9YeGFQdjVneVduMXZB?oc=5", "source_name": "Investing.com", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare disease hope stalls as eDSP trial fails and Quince halts development", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMjF5VTJaWWxBREY2Y3dFMnF4bnFrY29wRi1QbFJXd3JCVkF3TTlwQXpZbHUtQVRkUmFVUm9WWWMxcDVUN215TTFPZzcyeUNuT1JhUU5ZVmtuR3ZhTmdJcmVHbnJaamlsTXByZUw4Nk1MU3RXT1B0RG1uclBXalhtLVZ2NWFiN05aSjhaMkRUNzFzYzZlbmhEdkt3MW1ZNk5DaVozZjdtUnRtRlVLWGZvR0RlSHpIeDAtcGxZYUVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPSmpab2VPd0N3TGMtX3p3QTJjQmFQekFHWkFUd29VckdQMWRqc1F3SWxweFR2ang4Rl9SLXpfb1lQeVEzSVJGbVg2ZVVPTkQ2Z2hMSjI3dlZ5ekVTVnB0WFc1RkttLURBZkVaczNIcWZUcXo3OHZuakp3cU1xazhFeWliVGFETEU5YWw4bEJoUXlkeHM4YTIwREI2Z25NQ3NKRTFvakgxcnhuZXpfWjQ4VDRXamJ6MmswTGZuLXhFelllNDFrWkxhZnM4SzJ6Rl9xVUx0X1R6Zl9vcGhoTzhKNzg0aw?oc=5", "source_name": "Business Wire", "published_at": "2025-06-12T07:00:00+00:00", "published_display": "12 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince (QNCX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE0xZ3pSN29sR0NyamFHRHpBbElsN0ZRUm15d3h2TDh0VU4waUxRcUpEeS1ha0Zmcm01Tnc0R2pEd2RhTVh1dWNEaVVFVkcwVk5QYjl3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:36:57+00:00", "published_display": "25 Apr 2025 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quince Therapeutics (QNCX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBBNTY1cjVJSEliZkFkQnNkWE5SNDRGZ0VYcmRXMEhKaWhEd05uZnpfdllNN29iMFFNSlJUZmt0V3pweUdBVXhCaE9ZOW44OWxfeGhOU0dlbzlDZw?oc=5", "source_name": "MarketBeat", "published_at": "2022-08-04T13:01:09+00:00", "published_display": "04 Aug 2022 13:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 57, "sentiment_summary": {"positive": 13, "negative": 3, "neutral": 41, "score": 56, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 5.5, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 18.88, "latest_week": "2026-07-17", "one_week_move": 7.6, "four_week_move": -0.1, "twelve_week_move": -30.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.203606, "market_dynamics_buy_signal": false, "relative_strength": -93.422638, "fair_value_gap": -92.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.1873, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.6% over one week, -0.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "Moomoo", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 10}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.6% over one week, -0.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug"}], "updated_at": "2026-07-19T08:35:58.050797+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}